Emerging drugs for bipolar depression: an update

Bibliography

• Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 2007;64:543-52
   PubMed Web of Science ®Google Scholar
• Angst J, Cui L, Swendsen J, et al. Major depressive disorder with subthreshold bipolarity in the National Comorbidity Survey Replication. Am J Psychiatry 2010;167:1194-201
   PubMed Web of Science ®Google Scholar
• Angst J, Adolfsson R, Benazzi F, et al. The HCL-32: towards a self-assessment tool for hypomanic symptoms in outpatients. J Affect Disord 2005;88:217-33
   PubMed Web of Science ®Google Scholar
• Angst J, Sellaro R. Historical perspectives and natural history of bipolar disorder. Biol Psychiatry 2000;48:445-57
   PubMed Web of Science ®Google Scholar
• Soreca I, Frank E, Kupfer DJ. The phenomenology of bipolar disorder: what drives the high rate of medical burden and determines long-term prognosis? Depress Anxiety 2009;26:73-82
   PubMed Web of Science ®Google Scholar
• Smith DJ, Forty L, Russell E, et al. Sub-threshold manic symptoms in recurrent major depressive disorder are a marker for poor outcome. Acta Psychiatr Scand 2009;119:325-9
   PubMed Web of Science ®Google Scholar
• Baldessarini RJ, Vazquez G, Tondo L. Treatment of cyclothymic disorder: commentary. Psychother Psychosom 2011;80:131-5
   PubMed Web of Science ®Google Scholar
• Akiskal HS, Benazzi F, Perugi G, Rihmer Z. Agitated “unipolar” depression re-conceptualized as a depressive mixed state: implications for the antidepressant-suicide controversy. J Affect Disord 2005;85:245-58
   PubMed Web of Science ®Google Scholar
• Goodwin GM, Anderson I, Arango C, et al. ECNP consensus meeting. Bipolar depression. Nice, March 2007. Eur Neuropsychopharmacol 2008;18:535-49
   PubMed Web of Science ®Google Scholar
• Stender M, Bryant-Comstock L, Phillips S. Medical resource use among patients treated for bipolar disorder: a retrospective, cross-sectional, descriptive analysis. Clin Ther 2002;24:1668-76
   PubMed Web of Science ®Google Scholar
• Young AH, Rigney U, Shaw S, et al. Annual cost of managing bipolar disorder to the UK healthcare system. J Affect Disord 2011;133:450-6
   PubMed Web of Science ®Google Scholar
• Parker G, McCraw S, Hadzi-Pavlovic D, Fletcher K. Costs of the principal mood disorders: a study of comparative direct and indirect costs incurred by those with bipolar I, bipolar II and unipolar disorders. J Affect Disord 2013;149(1-3):46-55
   PubMed Web of Science ®Google Scholar
• Bond DJ, Lam RW, Yatham LN. Divalproex sodium versus placebo in the treatment of acute bipolar depression: a systematic review and meta-analysis. J Affect Disord 2010;124:228-34
   PubMed Web of Science ®Google Scholar
• Ghaemi SN, Gilmer WS, Goldberg JF, et al. Divalproex in the treatment of acute bipolar depression: a preliminary double-blind, randomized, placebo-controlled pilot study. J Clin Psychiatry 2007;68:1840-4
   PubMed Web of Science ®Google Scholar
• Davis LL, Bartolucci A, Petty F. Divalproex in the treatment of bipolar depression: a placebo-controlled study. J Affect Disord 2005;85:259-66
   PubMed Web of Science ®Google Scholar
• Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord 2013;15:1-44
   PubMed Web of Science ®Google Scholar
• Young AH, McElroy SL, Bauer M, et al. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry 2010;71:150-62
   PubMed Web of Science ®Google Scholar
• Weisler RH, Nolen WA, Neijber A, et al. Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study). J Clin Psychiatry 2011;72:1452-64
   PubMed Web of Science ®Google Scholar
• Baldessarini RJ, Tondo L, Davis P, et al. Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review. Bipolar Disord 2006;8(5 Pt 2):625-39
   PubMed Web of Science ®Google Scholar
• Gonzalez-Pinto A, Mosquera F, Alonso M, et al. Suicidal risk in bipolar I disorder patients and adherence to long-term lithium treatment. Bipolar Disord 2006;8(5 Pt 2):618-24
   PubMed Web of Science ®Google Scholar
• Bowden CL, Calabrese JR, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003;60:392-400
   PubMed Web of Science ®Google Scholar
• Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry 2009;194:4-9
   PubMed Web of Science ®Google Scholar
• van der Loos ML, Mulder PG, Hartong EG, et al. Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial. J Clin Psychiatry 2009;70:223-31
   PubMed Web of Science ®Google Scholar
• Haeberle A, Greil W, Russmann S, Grohmann R. Mono- and combination drug therapies in hospitalized patients with bipolar depression. Data from the European drug surveillance program AMSP. BMC Psychiatry 2012;12:153
   PubMed Web of Science ®Google Scholar
• Cohn JB, Collins G, Ashbrook E, Wernicke JF. A comparison of fluoxetine imipramine and placebo in patients with bipolar depressive disorder. Int Clin Psychopharmacol 1989;4:313-22
   PubMed Web of Science ®Google Scholar
• Amsterdam JD, Garcia-Espana F, Fawcett J, et al. Efficacy and safety of fluoxetine in treating bipolar II major depressive episode. J Clin Psychopharmacol 1998;18:435-40
   PubMed Web of Science ®Google Scholar
• Amsterdam JD, Shults J. Comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of bipolar type I and type II major depression–lack of manic induction. J Affect Disord 2005;87:121-30
   PubMed Web of Science ®Google Scholar
• Amsterdam JD, Shults J. Fluoxetine monotherapy of bipolar type II and bipolar NOS major depression: a double-blind, placebo-substitution, continuation study. Int Clin Psychopharmacol 2005;20:257-64
   PubMed Web of Science ®Google Scholar
• Parker G, Tully L, Olley A, Hadzi-Pavlovic D. SSRIs as mood stabilizers for Bipolar II Disorder? A proof of concept study. J Affect Disord 2006;92:205-14
   PubMed Web of Science ®Google Scholar
• McElroy SL, Weisler RH, Chang W, et al. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry 2010;71:163-74
   PubMed Web of Science ®Google Scholar
• Harel EV, Levkovitz Y. Effectiveness and safety of adjunctive antidepressants in the treatment of bipolar depression: a review. Isr J Psychiatry Relat Sci 2008;45:121-8
   PubMed Web of Science ®Google Scholar
• Prien RF, Klett CJ, Caffey EM Jr. Lithium carbonate and imipramine in prevention of affective episodes. A comparison in recurrent affective illness. Arch Gen Psychiatry 1973;29:420-5
   PubMed Web of Science ®Google Scholar
• Prien RF, Kupfer DJ, Mansky PA, et al. Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders. Report of the NIMH Collaborative Study Group comparing lithium carbonate, imipramine, and a lithium carbonate-imipramine combination. Arch Gen Psychiatry 1984;41:1096-104
   PubMed Web of Science ®Google Scholar
• Prien RF. NIMH report. Five-center study clarifies use of lithium, imipramine for recurrent affective disorders. Hosp Community Psychiatry 1984;35:1097-8
   PubMedGoogle Scholar
• Prien RF, Caffey EM Jr. Long-term maintenance drug therapy in recurrent affective illness: current status and issues. Dis Nerv Syst 1977;38:981-92
   PubMedGoogle Scholar
• Leverich GS, Altshuler LL, Frye MA, et al. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry 2006;163:232-9
   PubMed Web of Science ®Google Scholar
• Amsterdam JD, Shults J, Brunswick DJ, Hundert M. Short-term fluoxetine monotherapy for bipolar type II or bipolar NOS major depression - low manic switch rate. Bipolar Disord 2004;6:75-81
   PubMed Web of Science ®Google Scholar
• Ramasubbu R. Dose-response relationship of selective serotonin reuptake inhibitors treatment-emergent hypomania in depressive disorders. Acta Psychiatr Scand 2001;104:236-8; discussion 238-9
   PubMed Web of Science ®Google Scholar
• Post RM, Altshuler LL, Frye MA, et al. Rate of switch in bipolar patients prospectively treated with second-generation antidepressants as augmentation to mood stabilizers. Bipolar Disord 2001;3:259-65
   PubMed Web of Science ®Google Scholar
• Post RM, Altshuler LL, Leverich GS, et al. Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. Br J Psychiatry 2006;189:124-31
   PubMed Web of Science ®Google Scholar
• Pacchiarotti I, Bond DJ, Baldessarini RJ, et al. The International Society for Bipolar Disorders (ISBD) Task Force Report on Antidepressant Use in Bipolar Disorders. Am J Psychiatry 2013;170:1249-62
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Keck PE Jr, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005;162:1351-60
   PubMed Web of Science ®Google Scholar
• Thase ME, Macfadden W, Weisler RH, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol 2006;26:600-9
   PubMed Web of Science ®Google Scholar
• Young AH, Calabrese JR, Gustafsson U, et al. Quetiapine monotherapy in bipolar II depression: combined data from four large, randomized studies. Int J Bipolar Disord 2013;1; In press
   Google Scholar
• Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003;60:1079-88
   PubMed Web of Science ®Google Scholar
• Tohen M, Chengappa KN, Suppes T, et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry 2004;184:337-45
   PubMed Web of Science ®Google Scholar
• Tohen M, Chengappa KN, Suppes T, et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry 2002;59:62-9
   PubMed Web of Science ®Google Scholar
• Houston JP, Ahl J, Meyers AL, et al. Reduced suicidal ideation in bipolar I disorder mixed-episode patients in a placebo-controlled trial of olanzapine combined with lithium or divalproex. J Clin Psychiatry 2006;67:1246-52
   PubMed Web of Science ®Google Scholar
• Tohen M, Bowden CL, Smulevich AB, et al. Olanzapine plus carbamazepine v. carbamazepine alone in treating manic episodes. Br J Psychiatry 2008;192:135-43
   PubMed Web of Science ®Google Scholar
• Dierckx B, Heijnen WT, van den Broek WW, Birkenhager TK. Efficacy of electroconvulsive therapy in bipolar versus unipolar major depression: a meta-analysis. Bipolar Disord 2012;14:146-50
   PubMed Web of Science ®Google Scholar
• Bonds C, Frye MA, Coudreaut MF, et al. Cost reduction with maintenance ECT in refractory bipolar disorder. J ECT 1998;14:36-41
   PubMed Web of Science ®Google Scholar
• Connolly KR, Thase ME. Emerging drugs for major depressive disorder. Expert Opin Emerg Drugs 2012;17:105-26
   PubMed Web of Science ®Google Scholar
• Hayes J, Prah P, Nazareth I, et al. Prescribing trends in bipolar disorder: cohort study in the United Kingdom THIN primary care database 1995-2009. PLoS One 2011;6:e28725
   PubMed Web of Science ®Google Scholar
• Goldberg JF, Brooks JO III, Kurita K, et al. Depressive illness burden associated with complex polypharmacy in patients with bipolar disorder: findings from the STEP-BD. J Clin Psychiatry 2009;70:155-62
   PubMed Web of Science ®Google Scholar
• Takeda. Efficacy and safety of ramelteon sublingual in adult patients with acute depressive episodes associated with bipolar I disorder. Available from: http://clinicaltrials.gov/ct2/show/NCT01467700 [Last accessed 18 November 2013]
   Google Scholar
• Takeda. Safety and efficacy study of ramelteon (TAK-375) tablets for sublingual administration (SL) in adults with bipolar 1 disorder. Available from: http://clinicaltrials.gov/show/NCT01677182 [Last accessed 19 August 2013]
   Google Scholar
• Berwaerts J, Melkote R, Nuamah I, Lim P. A randomized, placebo- and active-controlled study of paliperidone extended-release as maintenance treatment in patients with bipolar I disorder after an acute manic or mixed episode. J Affect Disord 2012;138:247-58
   PubMed Web of Science ®Google Scholar
• Johnson & Johnson Pharmaceutical Research & Development LLC. Evaluation of effectiveness and safety of flexible-dose paliperidone extended release in patients with schizoaffective disorder. Available from: http://clinicaltrials.gov/ct2/show/results/NCT00412373 [Last accessed 18 May 2011]
   Google Scholar
• Forest Laboratories. Safety, tolerability, and efficacy of cariprazine for patients with bipolar depression. Available from: http://clinicaltrials.gov/ct2/show/NCT01396447 [Last accessed 19 November 2013]
   Google Scholar
• Laboratories F. Safety and efficacy of RGH-188 (Cariprazine) in bipolar depression. Available from: http://clinicaltrials.gov/ct2/show/NCT00852202 [Last accessed 25 February 2009]
   Google Scholar
• Otsuka Pharmaceutical Development & Commercialization I. A study of aripiprazole in patients with bipolar I disorder with a major depressive episode. Available from: http://clinicaltrials.gov/ct2/show/NCT00338273 [Last accessed 7 November 2013]
   Google Scholar
• Zarate CA Jr, Payne JL, Singh J, et al. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry 2004;56:54-60
   PubMed Web of Science ®Google Scholar
• Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry 2004;161:564-6
   PubMed Web of Science ®Google Scholar
• Perugi G, Toni C, Ruffolo G, et al. Adjunctive dopamine agonists in treatment-resistant bipolar II depression: an open case series. Pharmacopsychiatry 2001;34:137-41
   PubMed Web of Science ®Google Scholar
• Cassano P, Lattanzi L, Fava M, et al. Ropinirole in treatment-resistant depression: a 16-week pilot study. Can J Psychiatry 2005;50(6):357-60
   PubMed Web of Science ®Google Scholar
• Sheba Medical Center. A placebo controlled trial of the dopamine D-2 receptor agonist ropinirole in treatment of 60 patients with refractory bipolar depression. Available from: http://clinicaltrials.gov/ct2/show/NCT00335205 [Last accessed 8 June 2006]
   Google Scholar
• Teva Pharmaceutical Industries (Cephalon). Study to evaluate the efficacy and safety of armodafinil treatment as adjunctive therapy in adults with major depression associated with bipolar I disorder. Available from: http://clinicaltrials.gov/show/NCT01072630 [Last accessed 20 March 2013]
   Google Scholar
• Cusin C, Hilton GQ, Nierenberg AA, Fava M. Long-term maintenance with intramuscular ketamine for treatment-resistant bipolar II depression. Am J Psychiatry 2012;169:868-9
   PubMed Web of Science ®Google Scholar
• Burgdorf J, Zhang XL, Nicholson KL, et al. GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects. Neuropsychopharmacology 2013;38:729-42
   PubMed Web of Science ®Google Scholar
• Schaffer LC, Schaffer CB, Miller AR, et al. An open trial of pregabalin as an acute and maintenance adjunctive treatment for outpatients with treatment resistant bipolar disorder. J Affect Disord 2013;147:407-10
   PubMed Web of Science ®Google Scholar
• Pfizer. Study evaluating bifeprunox in bipolar depression. Available from: http://clinicaltrials.gov/ct2/show/NCT00134459 [Last accessed 12 February 2013]
   Google Scholar
• GlaxoSmithKline. Safety, tolerability and pharmacokinetics of repeat doses of GSK1014802. Available from: http://clinicaltrials.gov/ct2/show/NCT00908154 [Last accessed May 29, 2009]
   Google Scholar
• Zarate CA Jr, Quiroz JA, Singh JB, et al. An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry 2005;57:430-2
   PubMed Web of Science ®Google Scholar